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Fig. Risk-adjusted mortality based on age and ﬁrst dialysis access.
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dicted mortality and then to calculate odds ratios (OR).
Results: There were 343,645 patients in this cohort:
331,217 underwentNCS and 12,428 underwent cardiac sur-
gery. BB lowered the OR for mortality signiﬁcantly on NCS
patients with 3 to 4 cardiac risk factors (OR, 0.64; 0.46-
0.90). It had no effect on patients with 1 or 2 risk factors.
However, BB resulted in a signiﬁcantly higher chance of death
in NCS patients (OR 1.17; 1.04-1.31) with no risk factors.
Conclusions: In this large series, BB appears to be
beneﬁcial perioperatively in NCS patients with high cardiac
risk. However, the use of BB in NCS patients with no car-
diac risk factors should be avoided because of the increased
chance of death seen in this patient cohort.
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Objectives: Wound complications (WCs) negatively
impact lower extremity (LE) arterial reconstruction out-
comes. Acticoat Absorbent (Smith & Nephew, Inc) is a
moisture-absorbing alginate coated with nanocrystalline sil-
ver that delivers a sustained (3-day) dose of broadly antimi-
crobial silver ions. Via an investigator initiated clinical trial,
we tested the hypothesis that this silver-eluting topical sur-
gical dressing would lower WC rates in patients undergo-
ing open arterial LE procedures.
Methods: The study block-randomized 500 patients at
three institutions to standard gauze or silver alginate dress-
ings placed over incisions after LE arterial surgery. This orig-
inalORdressing remained until gross soiling, clinical need to
remove, or postoperative day 3 (whichever ﬁrst); subsequent
care was at provider discretion. The primary end point was
30-day WC incidence based on National Surgical Quality
Improvement Program guidelines. Demographic, clinical,
quality of life, and economic end points were also collected.
Results: Participants (70% male, 84% white; 45% with
diabetes; 31% with claudication [remainder critical limb
ischemia/aneurysm/revision]) had an overall 30-dayWC inci-
dence of 28%, with superﬁcial surgical site infection as themost
common (Table). In intent-to-treat analysis, silver alginate had
no impact on WC. In multivariable analysis, female sex (odds
ratio [OR], 1.6; 95% conﬁdence interval [CI], 1.04-2.58, P
¼ .034), ipsilateral incision length in cm (OR, 1.02; 95% CI,
1.01-1.03; P ¼ .002), and Coumadin (OR, 1.7; 95% CI,
1.02-2.85; P¼ .043) were signiﬁcantly associated with WCs.
Conclusions: The incidence of WCs remains high in
contemporary open LE arterial surgery. Under the study
conditions, a silver-eluting dressing had no effect on WC
incidence.Table. Worst wound complication by assigned dressing
Sterile SilverWound Status Ngauze alginate Totalo. (%) No. (%) No. (%)No wound complication 179 (72) 181 (72) 360 (72)
Hematoma, seroma, lymphatic complication 15 (6) 10 (4) 25 (5)
Dehiscence requiring local wound care 18 (7) 22 (9) 40 (8)
Superﬁcial surgical site infection 30 (12) 28 (11) 58 (12)
Deep surgical site infection 8 (3) 9 (4) 17 (3)
Total 250 250 500Author Disclosures: N. R. Barshes: Nothing to disclose;
M. Belkin: Nothing to disclose; A. D. Hamdan: Nothing
to disclose; N. D. Hevelone: Nothing to disclose; L. L.
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Objectives: Risk of death in dialysis patients is lowest
with arteriovenous ﬁstulas (AVFs), followed by arteriove-
nous grafts (AVGs) and then intravenous hemodialysis
catheters (IHCs). Our aim was to analyze the effect of
age on ﬁrst dialysis access outcomes.
Methods: All patients aged $18 years in the United
States Renal Data System (2006-2010) were analyzed.
Spline modeling and risk-adjusted Cox proportional hazard
models were used to analyze the effect of age on mortality
for ﬁrst dialysis access with AVF vs AVG vs IHC.
Results: The study analyzed 502,380 patients (63 6
15 years, 57% male, 41% mortality, followup 1.6 6 1.4
years). Increasing age was a signiﬁcant predictor of overall
